QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

Summary

This study will evaluate the safety, tolerability, and mechanism of action of multiple doses of QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis

Timeline

Start

2007-12

Primary completion

2009-04

Completion

—

Outcome

Outcome not reported

Stopped: “Concerns about risk of bronchoscopy procedure in the selected patient population and frequency of SAEs observed to date.”

Drugs

Indications